217 related articles for article (PubMed ID: 29781817)
1. Intravenous Immunoglobulin Therapy in Refractory Autoimmune Dysautonomias: A Retrospective Analysis of 38 Patients.
Schofield JR; Chemali KR
Am J Ther; 2019; 26(5):570-582. PubMed ID: 29781817
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for autoimmune autonomic ganglionopathy.
Iodice V; Kimpinski K; Vernino S; Sandroni P; Low PA
Auton Neurosci; 2009 Mar; 146(1-2):22-5. PubMed ID: 19056323
[TBL] [Abstract][Full Text] [Related]
3. Seronegative and seropositive autoimmune autonomic ganglionopathy (AAG): Same clinical picture, same response to immunotherapy.
Tijero B; Del Pino R; Pérez-Concha T; Acera MA; Gabilondo I; Berganzo K; Graus F; Martinez-Alday JD; Barcena J; Gómez-Esteban JC
J Neuroimmunol; 2018 Jun; 319():68-70. PubMed ID: 29685292
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory treatment in postural tachycardia syndrome: A case series.
Rodriguez B; Hoepner R; Salmen A; Kamber N; Z'Graggen WJ
Eur J Neurol; 2021 May; 28(5):1692-1697. PubMed ID: 33382525
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome.
Nosadini M; Mohammad SS; Suppiej A; Sartori S; Dale RC;
Dev Med Child Neurol; 2016 Nov; 58(11):1180-1192. PubMed ID: 27242065
[TBL] [Abstract][Full Text] [Related]
6. Acute dysautonomia: complete recovery after two courses of IVIg.
Ishitobi M; Haginoya K; Kitamura T; Munakata M; Yokoyama H; Iinuma K
Brain Dev; 2004 Dec; 26(8):542-4. PubMed ID: 15533658
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of immunologic abortion with low-dose intravenous immunoglobulin.
Stricker RB; Steinleitner A; Bookoff CN; Weckstein LN; Winger EE
Fertil Steril; 2000 Mar; 73(3):536-40. PubMed ID: 10689009
[TBL] [Abstract][Full Text] [Related]
8. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.
Dalakas MC
Neurotherapeutics; 2021 Oct; 18(4):2397-2418. PubMed ID: 34766257
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy.
Tenti S; Guidelli GM; Bellisai F; Galeazzi M; Fioravanti A
Clin Exp Rheumatol; 2013; 31(6):877-82. PubMed ID: 23985161
[TBL] [Abstract][Full Text] [Related]
10. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
[TBL] [Abstract][Full Text] [Related]
11. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events.
Seidling V; Hoffmann JH; Enk AH; Hadaschik EN
Acta Derm Venereol; 2013 May; 93(3):346-9. PubMed ID: 23073990
[TBL] [Abstract][Full Text] [Related]
12. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
Rigas M; Tandan R; Sterling RJ
J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
Ogata S; Ogihara Y; Honda T; Kon S; Akiyama K; Ishii M
Pediatrics; 2012 Jan; 129(1):e17-23. PubMed ID: 22144699
[TBL] [Abstract][Full Text] [Related]
14. Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg.
Turner LE; Pittock SJ; McEvoy MT; Flanagan EP
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31554670
[No Abstract] [Full Text] [Related]
15. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
16. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a single-center experience with 63 patients.
Nieto-Aristizábal I; Martínez T; Urbano MA; Posso-Osorio I; Plata IF; Garcia-Robledo JE; Aragón CC; Santos VA; Tobón GJ
Lupus; 2019 Nov; 28(13):1566-1570. PubMed ID: 31653191
[TBL] [Abstract][Full Text] [Related]
17. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.
Souayah N; Hasan A; Khan HM; Yacoub HA; Jafri M
J Clin Neuromuscul Dis; 2011 Jun; 12 Suppl 4():S1-10. PubMed ID: 22361589
[TBL] [Abstract][Full Text] [Related]
18. Intravenouse immunoglobuline in dysautonomia.
Gavrilova N; Kamaeva E; Ignatova M; Ryabkova V; Lukashenko M; Soprun L; Churilov LP; Shoenfeld Y
Clin Immunol; 2022 Jul; 240():109039. PubMed ID: 35569781
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin use for neurologic diseases.
Koski CL; Patterson JV
J Infus Nurs; 2006; 29(3 Suppl):S21-8. PubMed ID: 16878852
[TBL] [Abstract][Full Text] [Related]
20. Antibody titers predict clinical features of autoimmune autonomic ganglionopathy.
Gibbons CH; Freeman R
Auton Neurosci; 2009 Mar; 146(1-2):8-12. PubMed ID: 19144572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
